Polycystic Kidney Disease Affects PTH-Related Mortality
Very high and very low parathyroid hormone (PTH) levels are associated with the highest mortality rates in hemodialysis (HD) patients.
National Kidney Foundation Annual Meeting
Catheters Are the Most Common Vascular Access Type after Renal Allograft Failure
Central venous catheters are the most prevalent access type in patients who initiated hemodialysis (HD) following a failed renal transplant.
Iron Deficiency Common in CKD Patients
Researchers who studied a group of non-dialysis CKD patients found that about one quarter of them suffered from iron deficiency anemia.
Paricalcitol Improves Survival Regardless of Baseline iPTH Levels
Use of paricalcitol for hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) is associated with a significant improvement in survival independent of baseline levels of intact parathyroid hormone (iPTH) compared with patients who have untreated SHPT.
Phosphate Binder May Reduce the Number of Hospitalization Days
Using sevelamer instead of calcium-based binders (CBBs) to treat hyperphosphatemia in dialysis patients can significantly decrease the number of days of hospitalization.
Cinacalcet Plus Low-Dose Vitamin D May Slow CAC Progression
Cinacalcet plus low-dose vitamin D therapy may improve biochemical control of secondary hyperparathyroidism (SHPT) and attenuate progression of coronary artery calcification (CAC) compared with flexible vitamin D therapy alone in hemodialysis (HD) patients.
Sevelamer Carbonate May Impair Calcitriol Bioavailability
Sevelamer carbonate significantly decreases the bioavailability of oral calcitriol when the two drugs are administered together, but lanthanum carbonate does not, show data presented at the National Kidney Foundation’s 2010 Spring Clinical Meetings.
Fluid Intake with Phosphate Binders Quantified
The daily fluid intake with phosphate binder (PB) pills accounts for a significant portion of the daily fluid restriction in hemodialysis (HD) patients, suggest data presented at the National Kidney Foundation’s 2010 Spring Clinical Meetings.
Study Explores Novel Markers of CKD Anemia
Mitochondrial DNA copy number (mtDNA) and plasma levels of hepcidin hold promise as novel markers of anemia in CKD patients, suggest data introduced at the National Kidney Foundation’s 2010 Spring Clinical Meetings.
Paricalcitol-Treated Hemodialysis Patients May Require Less Erythropoietin
Long-term hemodialysis (HD) patients who receive paricalcitol as treatment for secondary hyperparathyroidism (SHPT) may require less erythropoietin than those who receive no SHPT treatment, according to new data presented at the National Kidney Foundation’s 2010 Spring Clinical Meetings.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...